



AllWays Formulary Changes Effective 1/1/22

1. Prefer Advair HFA, Advair Diskus, and Symbicort over fluticasone/salmeterol HFA, fluticasone/salmeterol Diskus, and budesonide-formoterol from formulary
 - Move Symbicort to generic tier
 - Move fluticasone/salmeterol HFA, fluticasone/salmeterol Diskus, and budesonide-formoterol to non-formulary
2. Prefer Ajoyv and Emgality over Aimovig.
 - Move all Emgality strengths to preferred tier
 - Move Aimovig to non-formulary
3. Update the quantity limit for Reyvow 50mg
 - Quantity limit will be 4 tablets initially, then 8 tablets per month
4. Prefer Wakix over Xywav and Xyrem
 - Add Wakix to preferred specialty tier
 - Update criteria to require failure of Wakix before Xywav or Xyrem
5. Prefer Vumerity over bafiertam
 - Add Vumerity to preferred specialty
 - Move bafiertam to non-formulary
 - Add PA to Zeposia to allow coverage for multiple sclerosis diagnosis
6. Prefer Praluent over Repatha
 - Move Repatha to non-formulary
7. Prefer both Entresto and Verquvo
 - Add Verquovo to preferred tier with step through Entresto
 - Keep PA on Entresto and remove quantity limit
8. Prefer Bosulif, Tasigna, and Sprycel over Iclusig
 - Will be reflected as preferred within formulary display
9. Prefer Kesimpta, Ocrevus, and Tysabri over Lemtrada
 - Add Kesimpta, Ocrevus, and Tysabri to the pharmacy benefit on the preferred specialty tier
 - Add Lemtrada to the pharmacy benefit on the non-preferred specialty tier
10. Low Cost Generics
 - Updates are being made to our low-cost generic list. This will only impact members on one of our 6 Tier plans.